Tiziana Life Sciences signed a memorandum with Saudi research organizations to pursue a clinical trial combining intranasal foralumab with anti-CD20 therapy in relapsing-remitting multiple sclerosis patients responding poorly to anti-CD20 treatment alone. The proposed collaboration broadens foralumab’s clinical development while the company’s non-active secondary progressive multiple sclerosis program continues unchanged.

Key Highlights

  • Tiziana and its collaborators intend to evaluate intranasal foralumab with existing anti-CD20 therapy in RRMS patients responding poorly to anti-CD20 therapy alone.
  • The memorandum was signed by Chief Executive Officer Ivor Elrifi during the Riyadh Global Medical Biotechnology Summit.
  • King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases are participating in the planned collaboration.

MOU Targets Combination Therapy in RRMS

The parties intend to evaluate Tiziana (NASDAQ: TLSA)’s proprietary intranasal foralumab alongside anti-CD20 therapy in the proposed trial. The memorandum was signed by Tiziana Chief Executive Officer Ivor Elrifi at an event held during the Riyadh Global Medical Biotechnology Summit in Riyadh on September 16, 2026.

Foralumab Has Reduced Neuroinflammation in Studies

Intranasal foralumab has reduced neuroinflammation in clinical studies to date, according to Tiziana. Tiziana said the proposed RRMS work represents an additional multiple sclerosis type beyond its ongoing non-active secondary progressive multiple sclerosis program. The company also said the new memorandum does not change its efforts in non-active secondary progressive multiple sclerosis.